Meta Healthcare
MedicineMH-910Orphan · EMA

MH-910

Fatty acid oxidation disorders

RegulatoryStage 5 of 6

A medicine under regulatory review in the European Union for a selected fatty acid oxidation disorder, with orphan designation previously granted.

Indication
Selected fatty acid oxidation indication
Patient population
Paediatric patients
Regulatory status
EU regulatory submission under review
Geography
United Kingdom · European Union
Partner status
Wholly owned

Under regulatory review. Subject to regulatory decision; not yet approved for marketing.

Information on this page describes products and programmes under development or commercialised by Meta Healthcare. Statements about development status and regulatory progress are factual and do not constitute claims of efficacy, superiority or regulatory certainty. Programmes under evaluation are not approved for marketing in all listed territories. Medical nutrition and medical food products should be used under the supervision of a healthcare professional.